Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Liquidity (Details Narrative)

Liquidity (Details Narrative) - USD ($)			1 Months Ended			2 Months Ended	3 Months Ended
Liquidity (Details Narrative) - USD ($)	May 01, 2020	Apr. 21, 2020	Jan. 31, 2020	Sep. 30, 2019	Nov. 30, 2018	May 31, 2020	Mar. 31, 2020	Mar. 31, 2019	Jun. 17, 2020	Dec. 31, 2019	Nov. 30, 2019	Jul. 31, 2019
Cash and cash equivalents							$ 13,370,000			$ 2,321,000
Accounts receivable, net							9,799,000			10,338,000
Total current assets							28,145,000			16,510,000
Total current liabilities							15,726,000			17,292,000
Net loss							6,494,000	$ 3,326,000
Net cash used in operating activities							7,122,000	$ 2,960,000
Line of credit facility							1,200,000			$ 3,000,000
Line of credit facility, remaining borrowing capacity							2,200,000
Public offering generating net proceeds							$ 200,000
Sale of common stock							97,817
Subsequent Event [Member]
Cash									$ 16,200,000
Silicon Valley Bank [Member]
Line of credit facility					$ 850,000
Line of credit facility, remaining borrowing capacity							$ 2,550,000
Line of credit facility term loan					3 years
Line of credit facility, description					The proceeds of the term loan are expected to be used for laboratory capital expenditures and will be repaid monthly. The balance of the Line of Credit is available for working capital purposes as a revolving line of credit and has a three-year term. The borrowing limit of the revolving line of credit is the lower of 80% of the Company's eligible accounts receivable (as adjusted by SVB) and the aggregate amount of cash collections with respect to accounts receivable during the three prior calendar months.		The amount that may be borrowed under the Revolving Line is the lower of (i) $3.75 million or (ii) 80% of the Company's eligible accounts receivable (as adjusted by SVB). Revolving Line outstanding amounts incur interest at a rate per annum equal to the Wall Street Journal Prime Rate plus 0.5%. The Company is also required to pay an unused Revolving Line facility fee monthly in arrears in an amount equal to 0.35% per annum of the average unused but available portion of the Revolving Line. The term loan portion of the SVB Loan Agreement has a maturity date of May 2, 2022, and the Revolving Line has a maturity date three years from the effective date, or November 13, 2021
Line of credit, percentage					0.50%
Silicon Valley Bank [Member] \| Prime Rate [Member]
Line of credit, percentage					5.00%		0.50%
Silicon Valley Bank [Member] \| Maximum [Member]
Line of credit facility											$ 4,000,000
Series B Preferred Stock [Member]
Public offering generating net proceeds			$ 19,500,000
Sale of common stock			20,000
Security Purchase and Exchange Agreement [Member]
Line of credit facility												$ 4,000,000
Equity Distribution Agreement [Member]
Public offering generating net proceeds				$ 4,800,000
ATM Agreement [Member]
Public offering generating net proceeds							$ 700,000
Sale of common stock							178,000
Centers for Medicare & Medicaid Services [Member] \| Subsequent Event [Member]
Loans payable	$ 2,100,000
Proceeds from loans payable	2,100,000
Department of Health and Human Services [Member] \| Subsequent Event [Member]
Loans payable	$ 650,000
Proceeds from loans payable		$ 650,000
Asset Purchase Agreement [Member] \| Subsequent Event [Member]
Proceeds from loans payable						$ 888,000
Asset Purchase Agreement [Member] \| Subsequent Event [Member] \| CGI Bio Pharma [Member]
Proceeds from loans payable						$ 888,000